Here’s why the Atomo (ASX:AT1) share price is soaring 10%

Personal rapid COVID-19 tests are in the news today, and the Atomo share price is benefitting.

| More on:
Graphic showing yellow arrow above vertical columns indicating a rising share price

Image source: Getty Images

The Atomo Diagnostics Ltd (ASX: AT1) share price is soaring today amid calls for the Australian government to approve rapid COVID-19 tests for personal use.

Atomo Diagnostics has partnered with Access Bio to create a rapid COVID-19 test. The test, named CareStart EZ COVID-19 test, has been approved for emergency use in the United States.

Right now, the Atomo Diagnostic share price is up 10%. The medical device company’s shares are trading for 23 cents apiece.

Let’s take a closer look at the news making headlines today.

Push for personal rapid COVID-19 tests

The Atomo Diagnostic share price is gaining amid reports state and federal governments are being lobbied to approve rapid COVID-19 tests for personal use.

According to reporting by, the Victorian Transport Association’s CEO Peter Anderson is pushing for personal rapid tests to be available to allow truck drivers to travel freely between states.

Anderson is also calling for more testing stations to be created on the border between NSW and Victoria.

Currently, truck drivers entering Victoria must receive a COVID-19 test every 3 days despite the results sometimes taking 3 days to be returned.

Additionally, ABC Radio reported this morning that the New South Wales government will soon announce a roadmap for Sydney’s next 4 weeks of lockdown, which may include personal rapid COVID-19 tests.

Numerous publications have reported NSW year 12 students might be among those using personal rapid COVID-19 tests.

However, the Royal College of Pathologists of Australasia has criticised the idea, saying they’re not accurate enough to be useful.

Finally, according to ABC News, Australia’s Health Department stated the tests aren’t useful when there are low rates of COVID-19 circulating.

Market watchers might be particularly excited about the Atomo Diagnostic share price today. That’s because the company’s rapid COVID-19 test has already been approved for use in Australian aged care homes.

Atomo Diagnostics share price snapshot

Despite today’s boost, the Atomo Diagnostic share price is still firmly in the red.

Right now, the Atomo Diagnostics share price is down 29% year to date.

The company has a market capitalisation of around $113 million, with approximately 586 million shares outstanding.

Should you invest $1,000 in Atomo Diagnostics right now?

Before you consider Atomo Diagnostics, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Atomo Diagnostics wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares